Therapeutic targeting of the E3 ubiquitin ligase SKP2 in T-ALL

[1]  J. Barata,et al.  IL-7R-mediated signaling in T-cell acute lymphoblastic leukemia: An update , 2019, Advances in biological regulation.

[2]  R. Mohammad,et al.  Dysregulated expression of SKP2 and its role in hematological malignancies , 2018, Leukemia & lymphoma.

[3]  K. Blackwell,et al.  HR+, HER2– Advanced Breast Cancer and CDK4/6 Inhibitors: Mode of Action, Clinical Activity, and Safety Profiles , 2017, Current cancer drug targets.

[4]  F. Locatelli,et al.  The combination of bortezomib with chemotherapy to treat relapsed/refractory acute lymphoblastic leukaemia of childhood , 2017, British journal of haematology.

[5]  A. Ferrando,et al.  The genetics and mechanisms of T cell acute lymphoblastic leukaemia , 2016, Nature Reviews Cancer.

[6]  Ellen V. Rothenberg,et al.  Developmental gene networks: a triathlon on the course to T cell identity , 2014, Nature Reviews Immunology.

[7]  D. Chen,et al.  Notch-dependent repression of miR-155 in the bone marrow niche regulates hematopoiesis in an NF-κB-dependent manner. , 2014, Cell stem cell.

[8]  Emma R. Andersson,et al.  Therapeutic modulation of Notch signalling — are we there yet? , 2014, Nature Reviews Drug Discovery.

[9]  Jon C. Aster,et al.  NOTCH1–RBPJ complexes drive target gene expression through dynamic interactions with superenhancers , 2013, Proceedings of the National Academy of Sciences.

[10]  M. Hung,et al.  Pharmacological Inactivation of Skp2 SCF Ubiquitin Ligase Restricts Cancer Stem Cell Traits and Cancer Progression , 2013, Cell.

[11]  C. Pui,et al.  Relapsed childhood acute lymphoblastic leukaemia. , 2013, The Lancet. Oncology.

[12]  J. Aster,et al.  Divergent effects of supraphysiologic Notch signals on leukemia stem cells and hematopoietic stem cells. , 2013, Blood.

[13]  M. Pagano,et al.  Specific small molecule inhibitors of Skp2-mediated p27 degradation. , 2012, Chemistry & biology.

[14]  J. Hazle,et al.  The Skp2-SCF E3 Ligase Regulates Akt Ubiquitination, Glycolysis, Herceptin Sensitivity, and Tumorigenesis , 2012, Cell.

[15]  J. Soulier,et al.  Therapeutic targeting of the cyclin D3:CDK4/6 complex in T cell leukemia. , 2012, Cancer cell.

[16]  Jung-Hyun Park,et al.  Intrathymic IL-7: the where, when, and why of IL-7 signaling during T cell development. , 2012, Seminars in immunology.

[17]  J. Hazle,et al.  The Skp2-SCF E3 Ligase Regulates Akt Ubiquitination, Glycolysis, Herceptin Sensitivity, and Tumorigenesis , 2012, Cell.

[18]  K. Nakayama,et al.  The SKP2 E3 ligase regulates basal homeostasis and stress-induced regeneration of HSCs. , 2011, Blood.

[19]  J. Aster,et al.  Notch signalling in T‐cell lymphoblastic leukaemia/lymphoma and other haematological malignancies , 2011, The Journal of pathology.

[20]  A. Ferrando,et al.  T-cell acute lymphoblastic leukemia in adults: clinical features, immunophenotype, cytogenetics, and outcome from the large randomized prospective trial (UKALL XII/ECOG 2993). , 2009, Blood.

[21]  A. Ferrando,et al.  CSL–MAML-dependent Notch1 signaling controls T lineage–specific IL-7Rα gene expression in early human thymopoiesis and leukemia , 2009, The Journal of experimental medicine.

[22]  Susan M. Schlenner,et al.  Faculty Opinions recommendation of CSL-MAML-dependent Notch1 signaling controls T lineage-specific IL-7R{alpha} gene expression in early human thymopoiesis and leukemia. , 2009 .

[23]  D. Koller,et al.  The Immunological Genome Project: networks of gene expression in immune cells , 2008, Nature Immunology.

[24]  J. Aster,et al.  Leukemia-associated NOTCH1 alleles are weak tumor initiators but accelerate K-ras-initiated leukemia. , 2008, The Journal of clinical investigation.

[25]  K. Nakayama,et al.  Absence of Skp2 Expression Attenuates Bcr-abl-induced , 2008 .

[26]  M. Pagano,et al.  Deregulated proteolysis by the F-box proteins SKP2 and β-TrCP: tipping the scales of cancer , 2008, Nature Reviews Cancer.

[27]  D. Hershko,et al.  Oncogenic properties and prognostic implications of the ubiquitin ligase Skp2 in cancer , 2008, Cancer.

[28]  A. Cardoso,et al.  Notch pathway is regulated by leukemia microenvironmental cues and positively modulates IL-7 signaling , 2007 .

[29]  U. Lendahl,et al.  Notch signaling induces SKP2 expression and promotes reduction of p27Kip1 in T-cell acute lymphoblastic leukemia cell lines. , 2007, Experimental cell research.

[30]  L. Appleman,et al.  CD28 Costimulation Mediates Transcription of SKP2 and CKS1, the Substrate Recognition Components of SCFSkp2 Ubiquitin Ligase That Leads p27kip1 to Degradation , 2006, Cell cycle.

[31]  J. Aster,et al.  Identification of a Conserved Negative Regulatory Sequence That Influences the Leukemogenic Activity of NOTCH1 , 2006, Molecular and Cellular Biology.

[32]  P. Kaldis,et al.  IL-7 promotes T cell proliferation through destabilization of p27Kip1 , 2006, The Journal of experimental medicine.

[33]  W. Gordon,et al.  Notch1 modulates timing of G1-S progression by inducing SKP2 transcription and p27Kip1 degradation , 2005, The Journal of experimental medicine.

[34]  Andrew P. Weng,et al.  Activating Mutations of NOTCH1 in Human T Cell Acute Lymphoblastic Leukemia , 2004, Science.

[35]  A. Ferrando,et al.  IL-7-dependent human leukemia T-cell line as a valuable tool for drug discovery in T-ALL. , 2004, Blood.

[36]  A. Ferrando,et al.  Requirement for cyclin D3 in lymphocyte development and T cell leukemias. , 2003, Cancer cell.

[37]  W. Pear,et al.  Notch and the immune system. , 2003, Immunity.

[38]  K. Nakayama,et al.  Degradation of p57Kip2 mediated by SCFSkp2-dependent ubiquitylation , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[39]  M. Pagano,et al.  Role of the SCFSkp2 Ubiquitin Ligase in the Degradation of p21Cip1 in S Phase* , 2003, Journal of Biological Chemistry.

[40]  S. Reed,et al.  The pRb-related protein p130 is regulated by phosphorylation-dependent proteolysis via the protein-ubiquitin ligase SCF(Skp2). , 2002, Genes & development.

[41]  J. Aster,et al.  Notch signaling in hematopoiesis and early lymphocyte development , 2002, Immunological reviews.

[42]  J. Barata,et al.  Interleukin-7 promotes survival and cell cycle progression of T-cell acute lymphoblastic leukemia cells by down-regulating the cyclin-dependent kinase inhibitor p27(kip1). , 2001, Blood.

[43]  M. Pagano,et al.  Role of the F-box protein Skp2 in lymphomagenesis , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[44]  M. Kitagawa,et al.  Down-Regulation of p27Kip1 Expression Is Required for Development and Function of T Cells1 , 2001, The Journal of Immunology.

[45]  M. Kaplan,et al.  Cytokine-Stimulated T Lymphocyte Proliferation Is Regulated by p27Kip1 1 , 2000, The Journal of Immunology.

[46]  M. Kitagawa,et al.  Targeted disruption of Skp2 results in accumulation of cyclin E and p27Kip1, polyploidy and centrosome overduplication , 2000, The EMBO journal.

[47]  Michele Pagano,et al.  SKP2 is required for ubiquitin-mediated degradation of the CDK inhibitor p27 , 1999, Nature Cell Biology.

[48]  J. Sklar,et al.  Notch1-Induced Delay of Human Hematopoietic Progenitor Cell Differentiation Is Associated With Altered Cell Cycle Kinetics , 1999 .

[49]  J. Sklar,et al.  Exclusive development of T cell neoplasms in mice transplanted with bone marrow expressing activated Notch alleles , 1996, The Journal of experimental medicine.